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The last decade has witnessed a remarkable increase in the number of effective treatment
options available for the management of patients with pulmonary arterial hypertension. In this
regard, agents belonging to the therapeutic classes that specifically target the prostacyclin,
endothelin and nitric oxide pathways have shown the greatest efficacy in clinical studies to
date. These various drug treatments have individually been shown to confer improvements
in symptoms, exercise capacity, pulmonary haemodynamics and possibly survival in different
patient subgroups. However, pulmonary arterial hypertension is characterised by dysregulation
of a variety of pathways. In addition, disease worsening is inevitable for the majority of
patients receiving monotherapy. As a consequence, there is increasing interest in the use of
treatment combinations in order to target multiple targets with the aim of restoring normal
pulmonary vascular function in order to improve clinical status. Indeed, use of multiple
specific-treatment regimens is now part of routine clinical practice and is emphasized in
recently published therapeutic guidelines. This review details the rationale for the different
combination strategies and examines the clinical evidence in favour of some of the approaches
that have been evaluated.
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Combination therapy in PAH S75Introduction
Pulmonary arterial hypertension (PAH) is an uncommon
clinical condition that is predominantly characterised by
uncontrolled remodelling and proliferation of the pulmo-
nary microcirculation.1 PAH is defined by a mean precapil-
lary pulmonary artery pressure (mPAP) of 25 mmHg at rest
with a normal (<15 mmHg) capillary wedge pressure in
patients that have no evidence of other causes of pulmo-
nary hypertension, such as associated lung, left heart or
chronic thromboembolic disease.2 In untreated patients,
there is a progressive increase in pulmonary vascular
resistance (PVR) that leads to intractable right ventricular
failure and premature death. It is now firmly established
that PAH develops when dysregulated expression and
activity of a variety of different vasoactive mediators lead
to disruption of the homeostatic mechanisms that govern
normal vascular function. Among others, deficiencies in the
production and lung expression of the endogenous vasodi-
lators prostacyclin and nitric oxide have been implicated in
disease pathogenesis, whereas an increase in the pulmo-
nary and circulating levels of the potent vasoconstrictor
endothelin has been shown to be aetiologically relevant.3
These observations led directly to the development of
three different classes of PAH-specific therapies that are
currently licensed for use in different forms of the disease:
prostacyclin analogues (prostanoids), endothelin antago-
nists and phosphodiesterase type-5 (PDE-5) inhibitors.
Prostacyclin is an arachidonic acid derivative that is
abundantly expressed in the pulmonary vascular endothe-
lium and exerts potent vasodilator, antithrombotic and
antiproliferative activity by acting on the adenosine
monophosphate cycle. The first synthetic prostacyclin to be
employed as replacement therapy in PAH was epoprostenol
which has been shown to confer improvements in symp-
toms, exercise capacity as measured by 6 min walk distance
(6 MWD) and pulmonary haemodynamics in PAH that is
idiopathic or associated with connective tissue disease
(CTD).4,5 Furthermore, epoprostenol remains the only
therapy to have demonstrated a survival benefit in PAH in
a randomised, placebo-controlled study.6 The main disad-
vantage of epoprostenol is its extremely short half-life,
necessitating continuous drug delivery via indwelling
central venous catheter. This fact has driven to the devel-
opment and formal evaluation of several other prostanoid
formulations that are easier to administer. When given by
the inhaled route, iloprost improves symptoms, modified
World Health Organization (WHO) functional class, exercise
capacity, pulmonary haemodynamics and quality of life.7
However, a minimum of six inhalations per day are
needed for therapeutic effect. Treprostinil has the advan-
tage of a longer half-life and is available in intravenous,
subcutaneous, inhaled and oral preparations. Treatment
with beraprost, another orally active prostanoid, was
shown to improve exercise capacity over a 12 week period;
however, beneficial effects do not appear to be sustained
with extended treatment duration.8
Endothelin-1 (ET-1) is a potent endogenous vasocon-
strictor and smooth muscle mitogen that is overexpressed
in the lungs and blood of PAH patients. The effects of ET-1
are mediated through its binding to two distinct receptorisoforms, termed ET-A and ET-B. The deleterious effects of
ET-1 are principally the result of activation of ET-A recep-
tors, which are predominantly found on smooth muscle cells.
Inhibition of the effects of ET-1 is therefore an appealing
therapeutic approach in PAH. The non-selective ET-A/ET-B
receptor antagonist bosentan was the first orally active
agent to be granted regulatory approval in PAH after
treatment-associated improvements in exercise capacity
were demonstrated in randomised studies compared to
placebo.9,10 Regulatory approval was initially granted for
patients with functional class III or IV symptoms, although
this licence was subsequently extended to those with milder
disease on the basis of more recent data.11 The hypothesis
that preservation of the salutary effects of ET-B receptor
activation might be preferable to dual receptor blockade led
to the development of the selective ET-A antagonists sitax-
sentan and ambrisentan. Both agents have been shown to
confer improvements in exercise capacity in prospective,
randomised, double-blind, placebo-controlled trials12,13 and
are licensed for use in various forms of PAH.
The potent vasodilator and antiproliferative activity of
nitric oxide is mediated via its associated downstream
second messenger signaling molecule, cyclic guanosine
monophosphate (cGMP). Degradation of cGMP is regulated
via the production of several distinct phosphodiesterase
(PDE) inhibitors. Within the pulmonary circulation, PDE-5 is
the most abundantly expressed isoform. This is of relevance
in PAH since treatments that act by inhibiting the activity of
PDE-5 have been shown to augment nitric oxide-mediated
pulmonary vasodilatation and also reverse vascular prolif-
eration via a pro-apoptotic effect on smooth muscle cells.
Sildenafil is an orally administered PDE-5 inhibitor that was
shown in a twelve-week, multicentre, placebo-controlled
trial involving 278 patients to improve 6 MWD, functional
class and pulmonary haemodynamics.14 In addition, long-
term follow-up data suggest a durable treatment effect
with sildenafil. Recently, another PDE-5 inhibitor, tadalafil,
was also granted regulatory approval on the basis of the
demonstration of favourable effects on exercise capacity
and quality of life and improvements in time to clinical
worsening.15
Rationale for combination therapy
A remarkable series of therapeutic advances has been
witnessed in the field of PAH over the last two decades.
Currently available therapies have been shown in
prospective clinical studies to impact favourably on
a variety of clinically relevant endpoints, such as patient
symptoms, exercise capacity, quality of life, pulmonary
haemodynamics and time to clinical worsening. There are
additional encouraging recent data that hint at an effect of
specific PAH therapy on mortality, which represents
perhaps the most important therapeutic goal.16 Despite this
progress, however, a cure for the disease remains elusive,
with eventual clinical deterioration observed in the
majority of PAH patients. Furthermore, the positive impact
on predefined clinical endpoints that has been reported in
randomised studies of different prostanoids, endothelin
antagonists and PDE-5 inhibitors is frequently modest. For
example, all of the currently approved agents have been
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normalization of exercise capacity is rarely reported. Thus,
limitation of normal daily activities remains a reality for
many individuals. Given these observations, investigators
have recently begun to formally assess whether combining
agents from different therapeutic classes might be
a worthwhile approach in the effort to delay progression of
disease (Table 1).
There are several theoretical advantages to adopting
a combination approach in PAH. It is now firmly established
that perturbations of a several important signaling pathways
is characteristic, irrespective of the underlying cause. This
being so, it is highly unlikely that focusing on a single thera-
peutic target in order to normalise any given aberrant
pathway will be consistently effective in ameliorating the
different manifestations of the disease. Treatment-related
side effects are often reported, particularly with prosta-
noids, with the result that dose escalation is limited. This
may account for the lack of efficacy that is observed in
certain patients receiving different forms of prostanoid.
Another potential drawback of prostanoids is that of tachy-
phylaxis, necessitating in some patients frequent dose
escalations in order to maintain clinical efficacy. Theoreti-
cally this problem, which occurs in those treated with pros-
tanoids, may be offset by the addition of sildenafil through
means of crosstalk between different pathways.17 However,
convincing evidence for a pharmacologically important
effect in vivo is lacking. Lastly, the use of combination
treatment regimens that exhibit different mechanisms of
action in an effort to maximise clinical gain is commonplace
in a variety of disorders. Indeed, a polypharmacologic
approach is standard of care in cardiac failure, human
immunodeficiency virus infection and various malignancies.Table 1 Clinical studies evaluating combination therapy in pul
Study Current therapy Added therapy Patients
(n)
Stud
dura
BREATHE-2 None Bosentan and
Epoprostenol
33 16 w
STEP-1 Bosentan Iloprost 67 12 w
COMBI Bosentan Iloprost 40 16 w
TRIUMPH-1 Bosentan
or sildenafil
Treprostinil
(inhaled)
235 12 w
FREEDOM-C Bosentan
and/or sildenafil
Treprostinil
(oral)
354 16 w
PACES Epoprostenol Sildenafil 267 16 w
PHIRST Naı¨ve or bosentan Tadalafil 405a (206) 16 w
EARLY Naı¨ve or sildenafil Bosentan 185a (29) 6 mo
a Total number of patients included (those receiving combination tr
b Clinical trials identifier NCT00325442.Prior to thedevelopmentof novel specificPAHtreatments,
therapeutic optionswereessentially limited to epoprostenol,
balloon atrial septostomy and lung transplantation. With the
increasing availability of different forms of therapy that act
on distinct pathways, a viable therapeutic alternative exists.
The publication of numerous individual reports and case
series describing beneficial effects of different combination
approaches eventually prompted investigators to conduct
a series of randomised studies in an effort to better define
whether this treatment philosophy had merit. However, the
ever-increasing range of drugs (and therefore possible
combinations) that may be employed has led to further
important questions that as yet remain unanswered. In
particular, it is unknown which combinations are the most
effective,when initiation of the selected combination should
beproposedandwhether seemingly ineffectiveagents should
be discontinued or maintained.Prostanoids and endothelin receptor
antagonists
The BREATHE-2 study was the first randomised, double-blind,
placebo-controlled clinical trial of combination therapy in
PAH.18 In order to compare the safety and efficacy of epo-
prostenol combined with bosentan to epoprostenol mono-
therapy, investigators enrolled 33 patients with PAH that was
either idiopathic or associated with CTD. All participants had
NYHA class III or IV symptoms and were initiated on epopros-
tenol for an initial period of 48 h. Thereafter, patients were
randomlyassigned toeitherbosentanorplacebo ina2:1 ratio.
At the end of 16 weeks follow-up, there was a greater
reduction in total pulmonary vascular resistance (tPVR)monary arterial hypertension.
y
tion
Primary
endpoint
Effects of combination
therapy
Reference
eeks PVR Non-significant reduction
in PVR
18
eeks 6MWD Delayed time to clinical
worsening and borderline
significant increase in 6MWD
19
eeks 6MWD Study terminated early 20
eeks 6MWD Placebo-adjusted increase
in 6MWD (þ20 m)
22
eeks 6MWD Non-significant increase
in 6MWD
b
eeks 6MWD Placebo-adjusted increase in
6MWD (þ28 m) and delayed
time to clinical worsening
23
eeks 6MWD Greater increase in 6MWD in
subgroup receiving baseline
bosentan
15
nths PVR/6MWD Improved haemodynamics and
delayed time to clinical
worsening in subgroup
receiving baseline bosentan
11
eatment are in brackets).
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those in the epoprostenol/placebo arm, though this differ-
ence did not reach statistical significance (36% vs. 22%
respectively, p Z 0.08). The combination treatment cohort
also showed improvements in mPAP, PVR and cardiac index
(CI) though none of these changes were significant. No
differences in 6MWD or functional class assessment were
observed between the two groups. Although treatment was
generally well tolerated overall, the combination therapy
cohort had a greater incidence of adverse events, most
notably oedemas, reductions in systolic blood pressure and
increases in heart rate. The relatively small study population
may inpartexplain theoverall lackofdifference in thevarious
endpoint variables between the treatment and placebo
groups, which might have become apparent in an adequately
powered trial. Furthermore, a greater proportion of sclero-
derma patients were randomised to the bosentan arm. Since
these patients are known to have a particularly poor prog-
nosis, this may also have skewed results.
A further multicentre study evaluating the safety and
tolerability of bosentan and prostanoid has been pub-
lished.19 The STEP-1 trial examined the outcomes of 67
patients treated for a minimum of four weeks with bosen-
tan who were randomised to receive add-on iloprost or
placebo in a double-blinded fashion. Study participants had
either NYHA functional class III (94%) or IV symptoms and
PAH that was idiopathic or associated with CTD or
congenital heart disease. Nebulizations were administered
six times per day for twelve weeks. At completion of the
study, the iloprost-treated arm had a placebo-adjusted
post-inhalation increase in 6MWD of 26 m, a change that
approached statistical significance (p Z 0.051). Improve-
ments in functional class by one class was observed in 34%
of iloprost versus 6% of placebo patients (p Z 0.002).
Although no improvements in the pre-inhalation pulmonary
haemodynamic profile were observed in the treatment
group, there was a significant delay in the time to clinical
worsening (0 events vs. 5 events in placebo-treated
patients; p Z 0.02). Treatment was generally well toler-
ated overall, with 90% of patients compliant with dosing
schedule. As expected, those receiving iloprost were more
likely to experience prostanoid-associated side effects. The
positive results from this trial led the US Food and Drug
Administration (FDA) to approve the combination of
bosentan and iloprost for use in PAH in 2005.
Interestingly, the positive results generated from the
STEP-1 study were not replicated in COMBI, another rando-
mised multicentre trial in which investigators examined the
impact of addition of inhaled iloprost in patients already
receiving bosentan therapy.20 The planned total recruitment
was 72 patients. However, the trial was suspended prema-
turely as a planned futility analysis following recruitment of
40 patients failed to showan improvement in 6MWD (placebo-
adjusted change ofþ10m) or time to clinical worsening. One
possible explanation for the discordance between the results
of the STEP-1 and COMBI trials is that patients with more
advanced disease were recruited to the latter study, as evi-
denced by lower values for 6MWD and CI at baseline.
The combination of bosentan and treprostinil has also
been investigated. Using a twelve-week, open-label study
design, Channick et al. observed significant improvements
from baseline in pulmonary haemodynamics, exercisecapacity and functional class when treprostinil (four inha-
lations daily) was introduced in patients with persistent
symptoms despite bosentan.21 This combination has the
additional advantage of reduced inhalation frequency and
shorter administration time with treprostinil compared to
inhaled iloprost.
Recently, the FDA approved inhaled treprostinil for use
in PAH associated with functional class III symptoms on the
basis of positive results of the as yet unpublished rando-
mised, double-blind, placebo-controlled TRIUMPH-1
study.22 In total, 235 patients who remained in functional
class III or IV despite maintenance oral therapy (bosentan or
sildenafil) were randomised to receive treprostinil (up to 56
mcg per treatment session) or placebo. After twelve weeks,
an increase in the median placebo-adjusted 6MWD of 20 m
(p < 0.0005) was demonstrated among the 212 patients who
completed the study. No difference was observed between
the groups in treatment-related changes in functional class
or episodes of clinical worsening.
In contrast to thefavourable resultsofcombination therapy
regimens using inhaled treprostinil, preliminary data suggest
that there may be no benefit derived from addition of oral
treprostinil to other oral PAH-specific therapies, as suggested
by the findings of the FREEDOM-C trial (www.clinicaltrials.gov
identifier NCT00325442). Investigators in this study enrolled
354 patients optimised on an endothelin receptor antagonist,
a PDE-5 inhibitor, or both to either oral treprostinil (titrated to
maximum tolerated dose) or placebo. Although there was
a trend to improvement in the combination group, the primary
efficacy endpoint of median change in 6MWD after sixteen
weeks was not met (þ11 m; pZ 0.072). Exploratory analyses
indicated that failure to dose titrate may have accounted for
the lack of benefit observed in the group receiving combina-
tion treatments in this study, since those individuals achieving
higher doses of treprostinil demonstrated greater improve-
ments in exercise capacity. Interestingly, the dose increments
that were employed in the early phase of this study appear to
have contributed to the significant patient drop out that was
observed overall. Whereas treatment discontinuation was
common in patientswhohad access only to 1mg tablets, there
were no dropouts due to adverse events among those who had
access to 0.25mg strength tablets, which became available to
patients subsequently.Prostanoids and PDE-5 inhibitors
In addition to the TRIUMPH-1 study, beneficial effects from
the combination of prostanoid and PDE-5 inhibitor have
been reported in the PACES trial, which addressed the
effects of addition of sildenafil to epoprostenol in 267 PAH
patients.23 Study participants with PAH that was idiopathic
or associated with anorexigen use, CTD or congenital heart
disease were randomised to placebo or sildenafil, titrated
from an initial 60 mg to a maximum of 240 mg in three
divided doses, as tolerated. At time of enrolment, all
patients had been treated with epoprostenol for a minimum
of three months without dose adjustment in the preceding
four weeks. Although the median epoprostenol dose was
nearly 30 ng/kg/min, doses as low as 3 ng/kg/min were
observed in the study. After sixteen weeks of treatment,
there was a placebo-adjusted increase in the 6MWD of 28 m
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group also demonstrated improvements in pulmonary hae-
modynamic indices and quality of life scores, and had
a longer time to clinical worsening. There were seven
deaths, which all occurred in the placebo group. The
combination was overall well tolerated with low rates of
serious adverse events and discontinuation of therapy. It is
important to note that the licensed dose of sildenafil on the
basis of the pivotal SUPER trial is 20 mg three times daily,14
which is lower than the maximum doses used in the PACES
study, though there is some evidence to suggest an incre-
mental benefit to higher doses.
Other published reports evaluating the effects of
inhaled iloprost and sildenafil are available. In a pilot study
involving five patients, concomitant administration of
these two treatments resulted in a more pronounced
reduction in mPAP than when either was given sepa-
rately.24 Two subsequent studies performed in Germany
demonstrated results that also suggest a potential thera-
peutic advantage in PAH with combined iloprost and sil-
denafil.25,26 However, there are as yet no data from
prospective randomised studies to support the use of this
therapeutic combination. Experience with sildenafil
combined with other forms of prostanoid is also limited to
case studies and small series.Endothelin receptor antagonists and PDE-5
inhibitors
Combined therapy with endothelin antagonists and PDE-5
inhibitors is a particularly appealing concept, since these
classes of agent are both orally administered, act on
different intracellular targets, and are generally well toler-
ated when given individually.27
The suitability of this dual oral therapy approach was
assessed as part of the PHIRST study, which was designed to
evaluate the safety and efficacy of different doses of the
once-daily dispensed selective PDE-5 inhibitor tadalafil.15 In
this randomised, double-blind, placebo-controlled trial,
approximately 50% of the 406 patients recruited were on
background bosentan therapy. Overall therewere favourable
results with treatment on 6MWD (þ32 m compared to
placebo), symptoms, pulmonary haemodynamics and time to
clinical worsening at the largest dose (40 mg) of tadalafil.
Subgroup analysis revealed that those receiving both drugs
had a further improvement of exercise capacity, though that
was of borderline significance. Results showed that the
overall placebo-adjusted increase in 6MWD was less in those
receiving combined tadalafil/bosentan compared to the
treatment-naı¨ve cohort. Although the clinical benefit derived
from co-treatment with tadalafil and bosentan was modest,
tadalafil has recently beenapproved for useby theFDAon the
basis of the overall positive results of the PHIRST study.
Recently, results from the EARLY study have been pub-
lished.11 The focus of this investigation was the evaluation
of the impact of bosentan treatment on PAH patients with
mildly symptomatic disease. A subset of patients (n Z 29)
enrolled in this trial were already receiving background
sildenafil and showed improvements in pulmonary haemo-
dynamics and delayed time to clinical worsening after
introduction of bosentan.Also underway is the ATHENA-1 study, which will eval-
uate changes in pulmonary haemodynamics following
addition of ambrisentan to treatment regimens in patients
with sub-optimal response to maintenance PD5-inhibitor
therapy (sildenafil or tadalafil). Secondary outcome
measures of change from baseline measurements in exer-
cise capacity, symptoms, functional class and brain natri-
uretic peptide levels will be assessed. Investigators will also
determine whether addition of ambrisentan will impact on
time to clinical worsening and survival. Total planned
recruitment for this 24 week follow-up study is 40 patients.
Implementation of combination therapy
An important question that remains unanswered is whether
sequential addition of treatments is preferable to upfront
combination approaches. A goal-oriented strategy to assist
timing of treatment escalation has previously been repor-
ted by Hoeper and colleagues.28 These authors used a pre-
defined set of treatment goals to guide therapeutic
decision making in 123 severe PAH patients. Using combi-
nations of bosentan, sildenafil, and inhaled iloprost survival
at 1, 2, and 3 years was 93.0%, 83.1%, and 79.9%, respec-
tively, representing significantly improved survivals
compared to a historical control group. In the subgroup of
patients who had idiopathic PAH, survival was also signifi-
cantly better than predicted based on the National Insti-
tutes of Health registry formula. Using the algorithm, 43.2%
of patients received dual therapy, and three drugs were
required in 16.1%. By contrast, the numbers requiring
parenteral prostanoid therapy or lung transplantation were
reduced.
To date, the only study to evaluate upfront combination
therapy in PAH was the BREATHE-2 trial. Further studies are
needed to establish whether a goal-oriented strategy
involving sequential addition of specific PAH agent is pref-
erable to initial combination approaches. Whichever option
is adopted, it is important to remember that potential drug
interactions may impact on therapeutic efficacy. There also
remains a need for additional long-term safety data when
multiple drugs, each of which has potential serious side
effects, are administered to patients.
Conclusion
Although the last decade has witnessed the development
and subsequent regulatory approval of several different
classes of PAH-specific treatment on the basis of amelio-
ration of a variety of clinically relevant endpoints, none of
the available agents is curative. Instead, the current ther-
apeutic goals for PAH patients include the improvement of
symptoms, exercise capacity, quality of life, pulmonary
haemodynamics and, ultimately, morbidity and mortality.
Previously, escalation of therapy was generally reserved for
patients that showed evidence of clinical worsening.
However, recently published guidelines have proposed
a more aggressive approach, advocating a paradigm shift in
therapeutic strategy in order to achieve treatment goals.2
It is now recommended that combination strategies
should be adopted for patients in functional class IIIeIV who
fail to improve as well as for individuals in class II with
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PAH-specific therapy is indicated to improve persistent
symptoms and reduced exercise capacity for those in
functional class III, whereas for those with functional class
II symptoms, maintenance of stable symptoms and 6MWD
disease is the goal. In cases where introduction of a second
therapeutic class of drug fails to achieve these targets,
triple combinations regimens may be considered.
Combination therapy for PAH is almost universally now
accepted as best clinical practice. However, a number of
important issues relating to this aspect of patient care
require further study. Given the lack of head-to-head
comparative analyses, it is currently unknown which of the
several possible combinations is most efficacious. Similarly,
addition investigation is required to establish whether an
upfront or sequential combination approach is preferable.
In general, the choice of treatments administered to
patients remains mostly dependent on physician experi-
ences and local preferences within the confines of regula-
tory approval by different agencies in individual countries.
Lastly, a critically important consideration is that of cost-
effectiveness, since polypharmacy in the context of PAH is
associated with significant cost implications for regional
health systems. Although many of the recently published
studies have demonstrated statistically significant differ-
ences in parameters such as 6MWD after introduction of
combination therapy, these changes often reflect only
modest improvements in exercise capacity. In this regard, it
is likely that the design of future randomised clinical
studies evaluating this approach will increasingly incorpo-
rate evaluation of more clinically relevant endpoints such
as time to clinical worsening and mortality. By this means,
it should be possible to identify which, if any, of the various
combination treatment strategies can improve long-term
disease control for patients.
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